BENIGN PROSTATIC HYPERPLASIA CELL LINE VIABILITY AND MODULATION OF JM-27 BY DOXAZOSIN AND IBUPROFEN
- 1 July 2005
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 174 (1), 375-379
- https://doi.org/10.1097/01.ju.0000161598.24740.34
Abstract
Benign prostatic hyperplasia (BPH) is among the most common diseases affecting quality of life in older men. Despise intense research efforts to our knowledge the genetic mechanisms underlying the BPH disease process and therapeutic markers needed to determine patient responsiveness to a particular form of pharmacological therapy are still not identified. This has slowed the development of new therapeutic agents for the treatment of BPH. We investigated the cellular effects of certain drugs on BPH. Besides doxazosin, which is the prevailing drug to treat BPH, the effect of ibuprofen was examined as a new therapeutic approach due to strong evidence of a correlation between BPH and inflammation. This study showed that doxazosin as well as ibuprofen significantly decreases cell viability and induced apoptosis in 267 B1 cells as well as in BPH-1 cells. In addition, we observed that the administration of doxazosin and ibuprofen to BPH-1 cells decreased the expression of JM-27, a protein particularly expressed in prostate that is highly up-regulated in symptomatic BPH. Our findings suggest that ibuprofen may be a new therapeutic target for the treatment of BPH. Further research must be done to investigate the potential use of ibuprofen in patients with BPH and examine if JM-27 expression in patients with BPH may stratify individuals who may be most responsive to pharmacological treatment.Keywords
This publication has 20 references indexed in Scilit:
- DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIAJournal of Urology, 2004
- The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic HyperplasiaNew England Journal of Medicine, 2003
- Fingerprinting the diseased prostate: Associations between BPH and prostate cancerJournal of Cellular Biochemistry, 2003
- Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancerThe Prostate, 2003
- Expression and function of pro‐inflammatory interleukin IL‐17 and IL‐17 receptor in normal, benign hyperplastic, and malignant prostateThe Prostate, 2003
- Increased expression of lymphocyte‐derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferationThe Prostate, 2002
- A Population-Based Study of Daily Nonsteroidal Anti-inflammatory Drug Use and Prostate CancerMayo Clinic Proceedings, 2002
- Immune response in hormonally-induced prostatic hyperplasia in the dogVeterinary Immunology and Immunopathology, 2001
- INDUCTION OF PROSTATE APOPTOSIS BY DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIAJournal of Urology, 1998
- Benign Prostatic HyperplasiaDrugs & Aging, 1997